Market Overview

Global Thyroid Gland Disorder Treatment Market to 2025 by Disease Type, Drug Type, Route of Administration, and Distribution/Sales Channel - ResearchAndMarkets.com

Share:

The "Thyroid
Gland Disorder Treatment Market by Disease Type, Drug Type, Route of
Administration, and Distribution/Sales Channel - Global Opportunity
Analysis and Industry Forecast, 2017-2025"
report has been
added to ResearchAndMarkets.com's offering.

The global thyroid gland disorder market was valued at $2,057 million in
2017, and is estimated to reach $2,771 million at a CAGR of 3.8% from
2018 to 2025.

North America was the highest contributor to the thyroid gland disorder
treatment market in 2017; however, Asia-Pacific is expected to witness
the highest growth during the forecast period.

The major factors that drive the growth of the thyroid gland disorder
market include increase in incidence of thyroid gland disorders,
development of effective combination thyroid disorders drug therapies,
and increase in number of disease awareness programs in developing
regions.

However, side effects of the medication and stringent government
regulations limit the market growth. Conversely, availability of large
pool of undiagnosed patients due to asymptomatic nature of thyroid
disorders in the emerging economies are anticipated to provide numerous
opportunities for the market growth during the forecast period.

Among the disease type, the hypothyroidism segment occupied the largest
share, and is anticipated to continue its dominance during the forecast
period, owing to the high prevalence of iodine deficiency population
worldwide, and is the most commonly occurring thyroid disorder.

Among the distribution channel, the wholesaler or distributor segment
occupied the largest share. However, mail-order pharmacy is the fastest
growing segment as these services help customers save money and
convenience.

Among the route of administration, the oral segment occupied the largest
share as most of the medications available in the market are in the form
of tablets or pills that can easily be administered by the patients.

Companies Profiled

  • Abbott Laboratories
  • AbbVie Inc.
  • Allergan Plc
  • GlaxoSmithKline Plc
  • Lannett Company Inc.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • RLC LABS Inc.

For more information about this report visit https://www.researchandmarkets.com/research/2xdr9j/global_thyroid?w=4

View Comments and Join the Discussion!